QuantaLife
Products and services for the life science research and clinical diagnostic markets.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
$162m Valuation: $162m | Acquisition | ||
| Total Funding | 000k | ||
QuantaLife, a subsidiary of Bio-Rad Laboratories, specializes in developing advanced multiplex immunoassay systems that enable the detection and quantification of multiple biomarkers, such as proteins, peptides, and nucleic acids, within a single sample. These systems are integral to life science research, clinical diagnostics, and biopharmaceutical processing. QuantaLife's core product, the Bio-Plex Multiplex Immunoassay System, includes instruments, software, calibration and validation tools, and multiplex assay kits, providing a comprehensive solution for high-throughput analysis. The company serves a diverse clientele, including university and research institutions, hospitals, public health and commercial laboratories, as well as biotechnology and pharmaceutical companies. Operating in the life sciences and healthcare markets, QuantaLife generates revenue through the sale of its sophisticated assay systems and related consumables, as well as through service contracts and support.
Keywords: multiplex immunoassay, biomarker detection, life science research, clinical diagnostics, biopharmaceutical processing, Bio-Plex system, high-throughput analysis, assay kits, biotechnology, healthcare.